Piperacillin-tazobactam Versus Carbapenem Therapy With and Without Amikacin as Empirical Treatment of Febrile Neutropenia in Cancer Patients: Results of an Open Randomized Trial at a University Hospital

Basit Öğe Kaydı
dc.contributor.authorÖztoprak, Nefise
dc.contributor.authorPişkin, Nihal
dc.contributor.authorAydemir, Hande
dc.contributor.authorÇelebi, Güven
dc.contributor.authorAkduman, Deniz
dc.contributor.authorKeskin, Ayşegül Seremet
dc.contributor.authorAnkaralı, Handan
dc.date.accessioned2020-04-30T23:20:59Z
dc.date.available2020-04-30T23:20:59Z
dc.date.issued2010
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.descriptionAnkarali, Handan Camdeviren/0000-0002-3613-0523;en_US
dc.descriptionWOS: 000280537500009en_US
dc.descriptionPubMed: 20427546en_US
dc.description.abstractEmpirical beta-lactam monotherapy has become the standard therapy in febrile neutropenia. The aim of this study was to compare the efficacy and safety of piperacillin-tazobactam versus carbapenem therapy with or without amikacin in adult patients with febrile neutropenia. In this prospective, open, single-center study, 127 episodes were randomized to receive either piperacillin-tazobactam (4 x 4.5 g IV/day) or carbapenem [meropenem (3 x 1 g IV/day) or imipenem (4 x 500 mg IV/day)] with or without amikacin (1 g IV/day). Doses were adjusted according to renal function. Clinical response was determined during and at completion of therapy. One hundred and twenty episodes were assessable for efficacy (59 piperacillin-tazobactam, 61 carbapenem). Mean duration of treatment was 14.8 +/- 9.6 days in the piperacillin-tazobactam group and 14.7 +/- 8.8 days in the carbapenem group (P > 0.05). Mean days of fever resolution were 5.97 and 4.48 days for piperacillin-tazobactam and carbapenem groups, respectively (P > 0.05). Similar rates of success without modification were found in the piperacillin-tazobactam (87.9%) and in the carbapenem groups (75.4%; P > 0.05). Fungal infection occurrence rates were 30.5 and 18% in piperacillin-tazobactam and carbapenem groups, respectively (P = 0.05). Antibiotic modification rates were 30.5 and 13.1% (P = 0.02) and the addition of glycopeptides to empirical antibiotic regimens rates were 15.3 and 44.3% for piperacillin-tazobactam and carbapenem groups, respectively (P = 0.001). The rude mortality rates were 14% (6/43) and 29.3% (12/41) in piperacillin-tazobactam and carbapenem groups, respectively (P = 0.08). The effect of empirical regimen of piperacillin-tazobactam regimen is equivalent to carbapenem in adult febrile neutropenic patients.en_US
dc.identifier.doi10.1093/jjco/hyq046en_US
dc.identifier.endpage767en_US
dc.identifier.issn0368-2811
dc.identifier.issue8en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage761en_US
dc.identifier.urihttps://doi.org/10.1093/jjco/hyq046
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4115
dc.identifier.volume40en_US
dc.identifier.wosWOS:000280537500009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofJapanese Journal Of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectfebrile neutropeniaen_US
dc.subjectgranulocytopeniaen_US
dc.subjectempirical therapyen_US
dc.subjectpiperacillinen_US
dc.subjecttazobactamen_US
dc.subjectcarbapenemen_US
dc.subjectmortalityen_US
dc.titlePiperacillin-tazobactam Versus Carbapenem Therapy With and Without Amikacin as Empirical Treatment of Febrile Neutropenia in Cancer Patients: Results of an Open Randomized Trial at a University Hospitalen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4115.pdf
Boyut:
115.72 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu